292 related articles for article (PubMed ID: 17516391)
1. Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient.
Pöhlmann C; Schetelig J; Reuner U; Bornhäuser M; Illmer T; Kiani A; Ehninger G; Jacobs E; Rohayem J
Clin Infect Dis; 2007 Jun; 44(12):e118-20. PubMed ID: 17516391
[TBL] [Abstract][Full Text] [Related]
2. Fatal HHV-6 associated encephalitis in an HIV-1 infected patient treated with cidofovir.
Astriti M; Zeller V; Boutolleau D; Gautheret-Dejean A; Allen G; Seilhean D; Agut H; Bricaire F; Katlama C; Bossi P
J Infect; 2006 Apr; 52(4):237-42. PubMed ID: 16188320
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet.
Hubacek P; Keslova P; Formankova R; Pochop P; Cinek O; Zajac M; Lochmanova J; Stary J; Sedlacek P
Pediatr Transplant; 2009 Nov; 13(7):919-22. PubMed ID: 19067913
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the clinical impact of acute human herpesvirus 6 (HHV-6) infections.
Agut H
J Clin Virol; 2011 Nov; 52(3):164-71. PubMed ID: 21782505
[TBL] [Abstract][Full Text] [Related]
5. [Salt-wasting nephropathy induced by foscarnet treatment for HHV-6 encephalitis in a hematopoietic stem cell transplant].
Najima Y; Ohashi K; Ando M; Koshida A; Yamashita T; Akiyama H; Sakamaki H
Rinsho Ketsueki; 2008 Jan; 49(1):40-5. PubMed ID: 18277595
[TBL] [Abstract][Full Text] [Related]
6. Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: breakthrough HHV-6 encephalitis following antiviral prophylaxis.
Ogata M; Satou T; Inoue Y; Takano K; Ikebe T; Ando T; Ikewaki J; Kohno K; Nishida A; Saburi M; Miyazaki Y; Ohtsuka E; Saburi Y; Fukuda T; Kadota J
Bone Marrow Transplant; 2013 Feb; 48(2):257-64. PubMed ID: 22750998
[TBL] [Abstract][Full Text] [Related]
7. Human herpes virus-6 encephalitis in a paediatric bone marrow recipient: successful treatment with pharmacokinetic monitoring and high doses of ganciclovir.
Janoly-Duménil A; Galambrun C; Basset T; Mialou V; Bertrand Y; Bleyzac N
Bone Marrow Transplant; 2006 Dec; 38(11):769-70. PubMed ID: 17013421
[No Abstract] [Full Text] [Related]
8. Human herpesvirus 6-related pure red cell aplasia, secondary graft failure, and clinical severe immune suppression after allogeneic hematopoietic cell transplantation successfully treated with foscarnet.
Lagadinou ED; Marangos M; Liga M; Panos G; Tzouvara E; Dimitroulia E; Tiniakou M; Tsakris A; Zoumbos N; Spyridonidis A
Transpl Infect Dis; 2010 Oct; 12(5):437-40. PubMed ID: 20561301
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid concentration of foscarnet in patients with HHV-6 encephalitis after haematopoietic stem cell transplantation.
Irie K; Hiramoto N; Yamaoka K; Fuckushima S
J Antimicrob Chemother; 2023 Jun; 78(6):1549-1551. PubMed ID: 37071595
[No Abstract] [Full Text] [Related]
10. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
[TBL] [Abstract][Full Text] [Related]
11. Posterior reversible encephalopathy syndrome concurrent with human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation.
Ito Y; Toyama K; Honda A; Nakazaki K; Arai S; Kurokawa M
J Infect Chemother; 2020 Feb; 26(2):265-268. PubMed ID: 31421950
[TBL] [Abstract][Full Text] [Related]
12. Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation.
Ishiyama K; Katagiri T; Ohata K; Hosokawa K; Kondo Y; Yamazaki H; Takami A; Nakao S
Transpl Infect Dis; 2012 Feb; 14(1):33-9. PubMed ID: 21794043
[TBL] [Abstract][Full Text] [Related]
13. Roseolovirus-associated encephalitis in immunocompetent and immunocompromised individuals.
Ongrádi J; Ablashi DV; Yoshikawa T; Stercz B; Ogata M
J Neurovirol; 2017 Feb; 23(1):1-19. PubMed ID: 27538995
[TBL] [Abstract][Full Text] [Related]
14. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation.
Chen Y; Scieux C; Garrait V; Socié G; Rocha V; Molina JM; Thouvenot D; Morfin F; Hocqueloux L; Garderet L; Espérou H; Sélimi F; Devergie A; Leleu G; Aymard M; Morinet F; Gluckman E; Ribaud P
Clin Infect Dis; 2000 Oct; 31(4):927-35. PubMed ID: 11049772
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.
Seo SK; Regan A; Cihlar T; Lin DC; Boulad F; George D; Prasad VK; Kiehn TE; Polsky B
Clin Infect Dis; 2001 Nov; 33(9):e105-8. PubMed ID: 11577375
[TBL] [Abstract][Full Text] [Related]
16. UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.
Gregg K; Hakki M; Kaul DR
Transpl Infect Dis; 2014 Apr; 16(2):320-3. PubMed ID: 24621186
[TBL] [Abstract][Full Text] [Related]
17. Human Herpesvirus 6B in the Transplant Recipient: When to Worry, When to Act.
Zerr DM
J Pediatric Infect Dis Soc; 2018 Dec; 7(suppl_2):S75-S78. PubMed ID: 30590622
[TBL] [Abstract][Full Text] [Related]
18. Characterizing human herpes virus 6 following hematopoietic stem cell transplantation.
Perissinotti AJ; Gulbis A; Shpall EJ; Howell J
J Oncol Pharm Pract; 2015 Apr; 21(2):85-92. PubMed ID: 24407957
[TBL] [Abstract][Full Text] [Related]
19. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir.
Neofytos D; Ojha A; Mookerjee B; Wagner J; Filicko J; Ferber A; Dessain S; Grosso D; Brunner J; Flomenberg N; Flomenberg P
Biol Blood Marrow Transplant; 2007 Jan; 13(1):74-81. PubMed ID: 17222755
[TBL] [Abstract][Full Text] [Related]
20. Human Herpesviruses 6A, 6B, and 7.
Agut H; Bonnafous P; Gautheret-Dejean A
Microbiol Spectr; 2016 Jun; 4(3):. PubMed ID: 27337451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
